Cemiplimab
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2].
Product Specifications
CAS Number
[1801342-60-8]
Product Name Alternative
REGN-2810; SAR-439684
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cemiplimab.html
Purity
99.89
Solubility
10 mM in DMSO
Smiles
[Cemiplimab]
Molecular Weight
(143.57 kDa)
References & Citations
[1]Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379 (4) :341-351.|[2]Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18 (11) :2051-2062.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6298914-01 0.2 mL
FGD2, CT (FGD2, ZFYVE4, FYVE, RhoGEF and PH domain-containing protein 2, Zinc finger FYVE domain-containing protein 4) (Biotin)
Ask
View Details MBS6298914-02 5x 0.2 mL
FGD2, CT (FGD2, ZFYVE4, FYVE, RhoGEF and PH domain-containing protein 2, Zinc finger FYVE domain-containing protein 4) (Biotin)
Ask
View Details 